Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Trinity Biotech PLC changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 23 | 1 | 20 | −2 |
| Shares | 1.07M | 5 | 993.0K | −80.0K (−7.5%) |
| Value | $588.9K | $3 | $379.5K | −$209.4K (−35.6%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Trinity Biotech PLC at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 26,859 | $10.4K | 0.00% |
| Advisor Group Holdings, Inc. | 3,500 | $1.36K | 0.00% |
Sold out (4)
Institutions that held Trinity Biotech PLC at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Yorkville Advisors Global, LP | 225,000 | $122.0K |
| Virtu Financial LLC | 26,676 | $14.0K |
| Renaissance Technologies LLC | 17,762 | $9.63K |
| Triumph Capital Management | 1,000 | $542 |
Not filed for Q2 2026 yet (1)
Institutions that held Trinity Biotech PLC at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| McIlrath & Eck, LLC | 5 | $3 |